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For some a magic bullet, for others, an unsafe experiment with human beings as the guinea
pigs, naltrexone implants and injections block the effects of heroin for weeks or months.
Naltrexone is an opiate antagonist which in itself has no psychoactive effects, but commandeers
the neural receptors targeted by opiate-type (‘opioid’) drugs. The implant form inserted under
the skin blocks opiates usually for two to six months; an intramuscular depot injection approved
for medical use in the USA and Russia lasts about a month. Both avoid the need to take
medication daily, in theory overcoming the main shortcoming of oral naltrexone – that patients
usually stop taking the tablets and resume heroin use.
We’ll see that while no instant solution, these preparations represent a valuable extension to the
range of interventions suitable sometimes for some people depending on their characteristics
and circumstances – in particular, those ready for abstinence from opioid drugs. As with other
approaches, the social and psychological adjustments needed to stabilise a non-addicted life are
likely to take time and require help which goes beyond medication, though this can help create
the space for such adjustments.
This hot topic concerns long-acting forms of naltrexone only and their use among usual
treatment populations. Another hot topic has narrowed in on the highly controversial practice of
coercing or forcing opiate-dependent offenders to enter naltrexone treatment.
Guidance reflects concerns over safety and efficacy
In the UK, neither implants nor depot injections of naltrexone have been licensed for medical
use. They can still be (and have been – 1 2 3 4) prescribed, but patient and doctor have to
accept the added responsibility of using a product which has not yet been shown to meet the
safety and efficacy requirements involved in licensing.
That too is the situation in Australia, where controversy over implants is at its height, one front
in the bitter battle between the supporters of harm reduction and methadone, and those who
see abstinence from legal and illegal opioids as the route to recovery. Fuelling the controversy is
widespread implant administration by some clinics in ways which both an advisory body set up
by (and in 2014 de-funded by) the national government and the doctors’ national association
believe circumvents regulatory procedures intended to assure quality, safety and efficacy. In
2012 the association found this “ethically problematic as it puts patients at risk of unknown
harms, for an unknown benefit”. Rather than being provided routinely, the doctors said such
untried medications should be reserved for patients facing impending death. After reviewing the
literature, the year before the Australian government’s National Health and Medical Research
Council had judged that naltrexone implants “remain an experimental product and should only
be used within a research setting”.
In the USA, two years after its approval for opioid dependence and six after being approved for
alcohol, in 2012 federal health service guidelines did not portray injectable naltrexone as a last
resort, but as one option among others suitable for a range of patients. By 2015 guidance on
treating opioid addiction from the American Society of Addiction Medicine was even more
relaxed about the risks, warning about post-treatment overdose in almost exactly the same
terms for the mainstream medications methadone and buprenorphine as for naltrexone. A sign
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of its acceptance in criminal justice circles, at the end of 2015 it was reported that around
100 US jails and prisons nationwide offered departing inmates injectable naltrexone to
reduce rates of re-addiction and re-incarceration.
Exposes philosophical divides over the nature of addiction
Aggravating concerns is the fact that commonly implants or injections are used after and
in conjunction with the precipitation of withdrawal from opiate-type drugs while patients
are anaesthetised or sedated. On safety grounds, British guidelines say the more radical
of these procedures entailing anaesthesia or deep sedation “must not be offered”, though
lighter forms of sedation are seen (1 2) as having a useful role while being less risky.
Tarnishing long-acting naltrexone with the risks of any preceding sedation or anaesthesia
would be unfair; in practice and in theory the procedures are distinct and separable,
long-acting naltrexone commonly being offered after conventional detoxification, and
rapid detoxification often being followed by oral naltrexone. However, there is an affinity
between the two procedures which both use medications to eliminate the patient’s
freedom to experience opiate-type drugs. Especially when used together, they raise
philosophical issues over the nature of addiction and its treatment. Withdrawal while
sedated or unconscious followed by naltrexone implants or injections promises a painless
technological fix to heroin addiction, within a day ridding the patient’s body of opiates and
then for months preventing further use, light-years from understandings of addiction as a
deeply rooted physical, psychological, social – even spiritual – condition, requiring effort
and life-transforming change to sustainably overcome.
Whether explicitly or not, such understandings may partly explain the slowness of take-up
of long-acting forms of naltrexone. Ironically, opiate-blocking implants/injections might
make it too easy to stay (more or less) abstinent from opiates. Official UKe guidance on
addiction treatment hints at just such a possibility. Here’s what it says about these
products’ possible role in abstinence-oriented rehabilitation programmes: “Is a resident to
whom a long-acting naltrexone formulation has been administered somehow going against
the ethos – and the interests of other residents – of a programme that lays great store on
(and expects of its other residents) strength of will and the ability to resist temptation in
the absence of any medicinal support?”
In such reservations, the committee behind the
guidance are not alone. Of long-acting injectable
naltrexone, the president of the Massachusetts branch
of the American Society of Addiction Medicine said: “Its
reputation on the street is that it’s a silver bullet … But
there is no way to heal from addiction without doing
the psychological work of recovery.” Even patients
insist recovery “requires effort and is not signified by easy gains. On the contrary,
recovery will likely hurt and cause pain.”
Another term for having “sustainably overcome” addiction is ‘recovery’, and here too
implant-supported remission might be seen as invalid. Against the yardstick of a
consensus UK definition, a recovery programme which just stops the user taking their
drug of addiction does not qualify as ‘recovery’ at all. It fails at the first criterion:
“voluntarily-sustained control over substance use”; the implant/injection is doing the
controlling, not the patient. Also these preparations do not in themselves do anything
“which maximises health and wellbeing and participation in the rights, roles and
responsibilities of society”. In fact, they might make these broader changes less likely,
because they are no longer needed to bolster abstinence.
It seems we face the curious possibility that precisely because a technology is (relatively)
effortlessly effective, it is to that degree under suspicion. Perhaps implicitly we believe
‘solutions’ to addiction must come from the inside, and suspect those seemingly
administered from the outside? Ironically, these misgivings are reminiscent of the reasons
which make some suspicious of an opposing technology – long-term maintenance not on
opiate blockers, but on opiate-type drugs themselves.
Such understandings imply that when an addict is suddenly denied opiate-based
amelioration of their life problems, these problems will be expressed or handled in some
other way, such as resort to non-opiate drugs, attempts to extract the implants, or severe
psychological distress. Add in the lack of official sanction from regulators and in some
circumstances the high cost to sometimes desperate patients and families, and the mix is
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one which arouses passions and exposes philosophical divides between those who
see addiction as a neural disorder amenable to technical ‘fixes’, and those who see
it as a whole-life pathology.
Lined up to reinforce these positions are practical and safety considerations which
the two sides see very differently. Proponents argue that long-acting naltrexone
offers a lifeline for addicts otherwise facing possibly years regularly attending
methadone clinics, one grasped by thousands when it is made available, but one
which pharmaceutical companies see as unprofitable. Especially without the backing
of big companies, seeking and awaiting the procedure’s official approval would, they
argue, have denied this opportunity to patients and families. Sceptics see the
enthusiasts as blinded by evangelical zeal, contending that that even apparent
lifelines need testing and approval before addicts are diverted from proven
approaches like methadone, which at least keep them alive and stable.
Further obscuring the issue of whether the procedure works is the allegedly
substandard practice at some clinics offering this treatment, tarnishing the
treatment itself with the shortcomings of its delivery vehicle. In relation to one
clinic headed not by a doctor but a psychologist, after the death of three former
patients in 2012 the Sydney Morning Herald reported “damning findings by the
state coroner and adverse evidence in three different disciplinary tribunals of the
medical, nursing and psychology professionsrdquo;. The coroner’s report was
scathing, counterpointing the “highly expensive” treatment with the impression
that the clinic was “run on a minimal expense basis”. Though the spotlight was
more on rapid opiate detoxification than naltrexone implants, the report suggested
both procedures have been implemented with inadequate assessment and follow-up
care.
Evidence limited but so far reassuring
Excess overdose deaths are the prime concern over oral naltrexone, and on this
score the long-acting versions have a reassuring record. As expected, studies of
naltrexone implants have found these protect against opiate overdose while they
are active, but also that overdose reductions have outlasted the active periods of
the implants. Among caseloads prepared to accept this treatment, long-acting
naltrexone seems a major advance on oral naltrexone in safety and effectiveness in
curbing illicit opiate use. However, this could partly be due to the weakness of the
psychosocial supports provided along with oral naltrexone. When these were
substantial, a US report found that still the high-dose, long-acting injection had an
appreciable overall advantage, but one which was due to impacts on the less
severely dependent patients. The more highly dependent actually did better with
the intensive support offered oral naltrexone patients. Though lapse to using
opiate-type drugs was common, after this possibly disappointing experience,
patients administered injectable naltrexone usually stopped using, while oral
naltrexone patients stopped attending for treatment.
Some studies (1 2 3 4 5) have shown that concerns that patients would try
non-opioid drugs as a way of sidestepping the naltrexone blockade have some
validity, others the opposite (1 2). Importantly, there are few reports of patients
taking dangerously prodigious quantities of opiates in attempt to override the
blockade.
These results though derive from a literature which is both small and
methodologically weak. Reviewing it in 2010, the Australian government’s National
Health and Medical Research Council remained unconvinced of the safety or
effectiveness of the implants, and was not reassured about the long-term overdose
risk after treatment has ended.
In particular, randomised trials have been rare. They include a Russian study
comparing long-acting injectable naltrexone to an identical placebo as a way of
sustaining abstinence after inpatient withdrawal. The active medication was much
more effective at suppressing opioid use. Far more so than placebo patients,
naltrexone patients had also reduced their risk of infection and experienced
improved health and quality of life. Particularly promising was that nearly 60% of
naltrexone patients were prepared to repeat the four-weekly injections over the full
24 weeks of the study. But even in this relatively promising caseload, for nearly
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half the patients, naltrexone injections and infrequent counselling were
insufficient to retain them in effective treatment.
The Russian trial was made more feasible by the absence of substitute
prescribing programmes, leaving varieties of opioid-free treatments the only
alternatives for patients. In Norway, substitute prescribing is available, but
restricted, creating another environment within which randomised trials are
more feasible. One trial similar to the Russian trial also delivered similar
findings, but in respect of the six-month implant. Despite a highly selected
and probably highly motivated caseload, over half the implant patients tried
resuming opioid use. Though the implant was expected to render such use
futile, repeated use did happen: on average the 12 of 23 followed-up implant
patients who used opioids had used these drugs on about 38 days out of the
roughly 180 days of the study. They did, however, use much less often than
comparison patients, and the figures were skewed by some very frequent
users.
A sister study (1 2) from the same research team in Norway randomly
allocated prisoners dependent on opiates before their sentence to naltrexone
implants or methadone maintenance to promote continuity of treatment on
release and avoid relapse. Generally neither was acceptable to the prisoners,
who felt (often falsely) that they could avoid relapse on their own. Among
the minority who did participate in the study, in the six months after release
crime and substance use reductions were not significantly greater with
implants than with methadone.
A criticism of these and other trials to date is that they have included highly
selected patients. However, in this they may have reflected normal practice.
Patients will only opt for such procedures if they are prepared (irreversibly in
the case of depot injections) to commit to possibly weeks or months without
the effects of heroin or other opiate-type drugs. From patients in naltrexone
implant/depot studies not allocated to these drugs, we know that even in
these caseloads, treatment drop-out and relapse are common. Long-acting
naltrexone helps these patients sustain their resolve.
A limitation of the studies is that only the better clinics are likely to invite
researchers in or cooperate with their work. Those (for example, in Eastern
Europe) which tempt UK-based addicts with low-cost detoxification and
naltrexone implants, but are in no position to offer psychosocial aftercare,
also cite no studies in their favour. What happens to patients after they visit
these clinics is unknown, and if it were known, might paint a less reassuring
picture of the overall safety and effectiveness of the procedure.
Who benefits?
The clearest candidates for the treatment are patients who are motivated
(perhaps due to employment or other pressures) to return to a life without
opiate-type drugs, and who have the resources, stability and support to
sustain this, are unlikely simply to use other drugs instead, but who when
free to experience heroin and allied drugs, cannot resist using them, possibly
reflected in their poor compliance with oral naltrexone treatment. Whatever
treatment is tried, it should be possible for patients to quickly and painlessly
revert to or try another if it does not work out.
Long-acting formulations may also be considered for unstable patients at
very high risk of overdose, but who will not accept or do poorly in substitute
prescribing programmes. Other candidates might include those unwilling or
unable to accept daily supervised consumption if this is a requirement of
being prescribed substitute medications.
US guidelines also suggest that people facing a time of severe stress or other
relapse-precipitants may benefit from the reassurance of the blockade. In
line with experience in Britain, the guidelines also highlight the injection’s
suitability for young adults, likely also to meet the criterion of having a short
or less severe history of dependence, and for methadone maintenance
patients who perhaps after years are stable enough to want to end their
dependence on methadone, and to have a good chance of doing so. Later
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guidance from the American Society of Addiction Medicine simply says
the injectable formulation is especially suitable for patients not in a
position to or unwilling to regularly take naltrexone tablets.
There are obvious reasons to be discriminating in the use of these
medications. If opiate-type drugs are supports relied on by vulnerable
individuals, naltrexone implants and injections suddenly remove this
support, and make it virtually impossible or difficult quickly to
resurrect it. Some patients can find replacement supports or sources of
resilience, others will flounder and fall. Undiscriminating advocacy of
the kind which alarmed an Australian coroner is clearly poor practice in
respect of any medication. Guidance is universally keen to emphasise
that implants and injections are not insert-and-go solutions. As with
methadone, patients should be regularly monitored, and those who
need this, supported to make the relapse-preventing life changes made
possible by a medication-aided space free from preoccupation with
obtaining and experiencing illegal opiates.
Thanks for their comments on this entry to Nikolaj Kunøe of the University of Oslo in
Norway, Duncan Raistrick, formerly Clinical Director at the Leeds Addiction Unit in
England, and Colin Brewer of the Stapleford Centre, also in England. Commentators
bear no responsibility for the text including the interpretations and any remaining
errors.
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